{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T06:39:48Z","timestamp":1777876788579,"version":"3.51.4"},"reference-count":26,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Nanoliposomal irinotecan combined with fluorouracil plus leucovorin (nal-IRI\u2009+\u20095-FU\/LV) is a standard second-line treatment for patients with advanced pancreatic cancer. Despite its efficacy, the prognostic factors for treatment efficacy remain unclear in clinical practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To investigate prognostic factors for survival with nal-IRI\u2009+\u20095-FU\/LV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Single-centre retrospective cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We included 204 patients who were treated with nal-IRI\u2009+\u20095-FU\/LV at our institution between July 2020 and March 2022. These patients had unresectable or recurrent pancreatic adenocarcinoma refractory to a gemcitabine-containing regimen. A Cox regression hazard model was used to explore prognostic factors for overall survival (OS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 204 eligible patients, 127 (64%) had received only one prior treatment. Most patients (90%) had metastatic disease, with 93, 61 and 55 patients having metastases to the liver, lungs and peritoneum, respectively. Among them, 18 patients had peritoneal metastasis without ascites. The median OS and progression-free survival (PFS) were 8.7 (95% confidence interval (CI), 7.5\u20139.8) and 3.6 (95% CI, 3.0\u20134.2)\u2009months, respectively. An Eastern Cooperative Oncology Group performance status (PS) of 0, serum albumin (Alb) level \u2a7e3.5\u2009g\/dL, C-reactive protein (CRP) level &lt;0.5\u2009mg\/dL, carbohydrate antigen 19-9 (CA 19-9) level &lt;1000\u2009U\/mL and peritoneum metastasis without ascites were independent prognostic factors for OS. The hazard ratios for these factors were 2.08, 1.96, 2.34, 2.22 and 1.92 with\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      -values of \u2a7d0.001, 0.001, &lt;0.001, &lt;0.001 and 0.043, respectively. Peritoneal metastasis, with or without ascites, was associated with 2-year OS rates compared to those without: 14.5% versus 6.0%, and 27.8% versus 6.5% (\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      -value\u2009=\u20090.053 and 0.010, respectively).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>A PS of 0, Alb &gt;3.5\u2009g\/dL, CRP &lt;0.5\u2009mg\/dL, CA 19-9 &lt;1000\u2009U\/mL and the presence of peritoneal metastasis, especially without ascites, were favourable prognostic factors for survival in patients with advanced pancreatic cancer treated with nal-IRI\u2009+\u20095-FU\/LV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359251351540","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T06:20:07Z","timestamp":1750918807000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Peritoneum carcinomatosis as a favourable prognostic factor for treatment with nanoliposomal irinotecan and fluorouracil plus leucovorin in advanced pancreatic cancer"],"prefix":"10.1177","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2535-6586","authenticated-orcid":false,"given":"Satoshi","family":"Kobayashi","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center, 2-3-2, Nakao, Asahi-ku, Yokohama 241-0815, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taito","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shun","family":"Tezuka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Shiraishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Enomoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Tsunoda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Hamaguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritsuko","family":"Ohishi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Tozuka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaaki","family":"Murakawa","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Yokohama City University, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,6,26]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"International Agency for Research on Cancer. GLOBOCAN https:\/\/gco.iarc.fr\/ (accessed 28 August 2024)."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369"},{"key":"e_1_3_4_5_2","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Pancreatic adenocarcinoma. Version 3.2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf (accessed 28 August 2024)."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00986-1"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3558"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2018.12.007"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.12.014"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-024-02834-0"},{"key":"e_1_3_4_11_2","unstructured":"The Strengthening the Reporting of Observatinal Studies in Epidemiology (STORBE) Statement. Equator Network https:\/\/www.equator-network.org\/reporting-guidelines\/strobe\/ (accessed 5 April 2025)."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2565"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30074-7"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000001455"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v13.i2.224"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.332"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602760"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2024.06.004"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.145389"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.31557\/APJCP.2024.25.10.3413"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-022-12723-6"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2019.03.035"},{"key":"e_1_3_4_24_2","article-title":"Nanoparticle albumin\u2011bound paclitaxel and solvent-based paclitaxel as chemotherapy options for patients with advanced gastric cancer: a systematic review and meta-analysis","volume":"15","author":"Gangannapalle M","year":"2023","unstructured":"Gangannapalle M, Shahnoor H, Sattar L, et al. Nanoparticle albumin\u2011bound paclitaxel and solvent-based paclitaxel as chemotherapy options for patients with advanced gastric cancer: a systematic review and meta-analysis. Cureus 2023; 15: e41711.","journal-title":"Cureus"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-017-2132-4"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2025.02.035"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2020.10.029"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251351540","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359251351540","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359251351540","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T22:32:47Z","timestamp":1777588367000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359251351540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":26,"alternative-id":["10.1177\/17588359251351540"],"URL":"https:\/\/doi.org\/10.1177\/17588359251351540","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17588359251351540"}}